Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29

M. Correale, I. Abbate, G. Gargano, A. Catino, C. D. Dragone, M. D. Musci, G. Serio, A. Paradiso, M. De Lena

Research output: Contribution to journalArticlepeer-review


Evaluation of a radioimmunoassay for a new tumor marker, named CA 27.29, recently proposed for use in breast cancer patients, is reported in this study. After considering the analytical performance, the clinical study was directed to a control group of 66 apparently healthy subjects (Controls), a group of 25 women with benign breast disease (BBD) and a group of 164 breast cancer patients divided into primary before any treatment (M-), in follow-up with no evidence of disease (NED) and presence of metastases (M+). When compared to CA 15.3, our results showed similar sensitivity of both markers with a slightly lower specificity for CA 27.29. In some cases, however, CA 27.29 elevation appears earlier than CA 15.3 as a sign of metastases. We thus propose their associated use.

Original languageEnglish
Pages (from-to)43-46
Number of pages4
JournalInternational Journal of Biological Markers
Issue number1
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Biochemistry
  • Immunology


Dive into the research topics of 'Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29'. Together they form a unique fingerprint.

Cite this